TORONTO, ONTARIO -- (Marketwired) -- 02/27/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) will report its financial results for the 3 month and 12 month periods ended December 31, 2013 on Wednesday, March 5th 2014 after market close.
Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Thursday, March 6th 2014, at 8:30 a.m. Eastern Standard Time. Following the discussion, Trimel executives will address inquires from investment analysts.
To access the call live, please dial 416-340-2216 or 1-866-223-7781. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.
A replay of the conference call will be available until 7:00 p.m. Eastern Standard Time on Thursday, March 13th, 2014 by dialing 905-694-9451 or 1-800-408-3053, using access code: 7051335#.
For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at ir@trimelpharmaceuticals.com.
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. An NDA for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.
Contacts:
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
(416) 679-0536
ir@trimelpharmaceuticals.com
www.trimelpharmaceuticals.com